Alison Nankervis

Alison Nankervis

Auto-generated profile, based on publicly available information

Alison Nankervis

Department of Medicine, University of Melbourne, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Obesity
Verified
Journal Article
Open access
PDF file
SPSarah Anna Lucy Price
Sarah Anna Lucy Price
PSPriya Sumithran
Priya Sumithran
ANAlison J. Nankervis
Alison J. Nankervis
MPMichael Permezel
Michael Permezel
LPLuke Prendergast
Luke Prendergast
JPJoseph Proietto
Joseph Proietto
Objective: This study examined the effectiveness of a nonsurgical, preconception weight loss intervention on pregnancy outcomes in women with obesity.Methods: This was a two‐arm, parallel‐group randomized controlled trial. A total of 164 women with BMI 30 to 55 kg/m2 who were aged 18 to 38 years and planning pregnancy were randomized to a 12‐week standard dietary intervention (SDI; n = 79) or a modified very low‐energy diet (VLED; n = 85). Participants were observed for ≤48 weeks while trying for pregnancy and then during pregnancy. The primary outcome was maternal fasting plasma glucose at 26 to 28 weeks’ gestation. Exploratory outcomes were individual and composite obesity‐related adverse pregnancy outcomes.Results: Weight loss was greater in the VLED group (SDI 3.2 [0.6] kg vs. VLED 13.0 [0.5] kg, p < 0.01). In completers who had a singleton live birth (SDI 22/79 vs. VLED 35/85, p = 0.10), there was no difference in fasting glucose at 26 to 28 weeks’ gestation (SDI 4.8[0.2] mmol/L vs. VLED 4.6 [0.1] mmol/L, p = 0.42). However, the composite of adverse pregnancy outcomes was significantly lower in the VLED group (p < 0.001).Conclusions: Substantial prepregnancy weight loss in women with obesity does not alter fasting glucose at 26 to 28 weeks’ gestation but does reduce a composite of adverse pregnancy outcomes. A better understanding of metabolic changes in pregnancy after preconception weight loss may assist in improving maternal and neonatal health outcomes.

21 February 2014 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
HSHelen Skouteris
Helen Skouteris
HMHeather Morris
Heather Morris
CNCate Nagle
Cate Nagle
ANAlison Nankervis
Alison Nankervis

19 June 2024 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
FWFelicia Widyaputri
Felicia Widyaputri
EKEdmund W. C. Khong
Edmund W. C. Khong
SRSophie L. Rogers
Sophie L. Rogers
ANAlison J. Nankervis
Alison J. Nankervis
JCJennifer J. Conn
Jennifer J. Conn
LLLyndell Lim
Lyndell Lim
Background: Diabetic retinopathy (DR) may worsen during pregnancy, but its course in the postpartum remains poorly understood. Understanding the natural history of DR during and after pregnancy can help determine when sight‐threatening DR treatment should be administered.Methods: A prospective longitudinal cohort study recruited pregnant women with pre‐existing type 1 (T1D) or type 2 diabetes from two tertiary Diabetes Antenatal Clinics in Melbourne, Australia. Eye examination results in early pregnancy, late pregnancy, and up to 12‐months postpartum were compared to determine DR changes. Two‐field fundus photographs and optical coherence tomography scans were used to assess DR severity.Results: Overall, 105 (61.4%) women had at least two eye examinations during the observation period. Mean age was 33.5 years (range 19–51); 54 women (51.4%) had T1D; 63% had HbA1c <7% in early pregnancy. DR progression rate was 23.8% (95% CI 16.4–32.6). Having T1D (RR 4.96, 95% CI 1.83–13.46), pre‐existing DR in either eye (RR 4.54, 95% CI 2.39–8.61), and elevated systolic blood pressure (adjusted RR 2.49, 95% CI 1.10–5.66) were associated with increased risk of progression. Sight‐threatening progression was observed in 9.5% of women. Among the 19 eyes with progression during pregnancy, 15 eyes remained stable, three eyes progressed, and only one eye regressed in the postpartum.Conclusions: Nearly 1 in 4 women had DR progression from conception through to 12‐months postpartum; almost half of these developing sight‐threatening disease. DR progression occurring during pregnancy was found to predominantly remain unchanged, or worsen, after delivery, with very few eyes spontaneously improving postpartum.

12 January 2021 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
CHChristel Hendrieckx
Christel Hendrieckx
MMMelinda Morrison
Melinda Morrison
RARalph Audehm
Ralph Audehm
ABAlison Barry
Alison Barry
KFKaye Farrell
Kaye Farrell
GRGlynis Ross
Glynis Ross

11 April 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
SPSarah Anna Lucy Price
Sarah Anna Lucy Price
DKDigsu N Koye
Digsu N Koye
ALAlice Lewin
Alice Lewin
ANAlison Nankervis
Alison Nankervis
SKStefan Charles Kane
Stefan Charles Kane
Background: Metabolic disease is increasingly impacting women of reproductive age. In pregnancy, uncontrolled metabolic disease can result in offspring with major congenital anomalies, preterm birth, and abnormal fetal growth. Pregnancy also accelerates the complications of metabolic diseases in mothers resulting in an increased risk of premature cardiovascular events. Despite the convincing evidence that preconception care can largely mitigate the risks of metabolic disease in pregnancy, there are few data about how to identify the highest-risk women so that they can be connected with appropriate preconception care services. Objective: The aim of the study is to determine the maternal phenotype that represents the highest risk of having adverse neonatal and maternal pregnancy outcomes. Methods: This will be a prospective cohort study of 500 women recruited in early pregnancy. The primary outcome is a composite of offspring born small for gestational age (SGA) or large for gestational age (LGA) (customized birthweight ≤10th and ≥90th centile for gestational age). Secondary outcomes are (1) composite of adverse neonatal birth outcomes (SGA, LGA, major congenital abnormalities, preterm birth [<37 weeks’ gestation]) and (2) composite of new maternal metabolic outcomes (gestational diabetes, diabetes in pregnancy, type 2 diabetes [T2D] or prediabetes; gestational hypertension, preeclampsia, eclampsia or new essential hypertension after pregnancy; and gestational weight gain ≥20kg or new overweight/obesity at the 12-18 months postpartum visit). A multivariable logistic regression analysis will be conducted to identify candidate predictors of poor pregnancy outcomes due to metabolic disease. From this model, model coefficients and the associated 95% CIs will be extracted to derive the risk score for predicting the delivery of LGA/SGA offspring (primary outcome) and composites of adverse neonatal outcomes and maternal outcomes (secondary outcomes). Results: Seed funding for the project was acquired in November 2022 and subsequent funding was acquired in May 2024. The first participant was recruited on March 23, 2023. At the time of manuscript submission, 402 participants have been recruited. Data analysis has not yet been performed. Results are expected to be published in the first half of 2027. Conclusions: This is a prospective observational cohort study that intends to identify the metabolic disease risk factors, or combination of factors, that are most likely to cause adverse maternal and fetal health outcomes. These characteristics will be used to develop a risk calculator which will assist in identifying the highest risk women and in triaging them to appropriate services. The study has been approved by the institutional Human Research Ethics Committee (HREC/90080/MH-2022). Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12623000037606; https://tinyurl.com/yeytsxtp International Registered Report Identifier (IRRID): DERR1-10.2196/72542

7 November 2024 in Clinical Obesity
Verified
Journal Article
Closed access
SPSarah Anna Lucy Price
Sarah Anna Lucy Price
ALAlice Lewin
Alice Lewin
ANAlison Nankervis
Alison Nankervis
RBRahul D Barmanray
Rahul D Barmanray